Towards sustained delivery of small molecular drugs using hydroxyapatite microspheres as the vehicle

The aim of this work is to explore the possibilities of using hydroxyapatite microspheres (HAP-MS) and polymer coated HAP-MS as the vehicles for the sustained release of small molecular drugs. The adsorption/desorption behaviors of model drug, doxycycline hydrochloride (Dox·HCl), on HAP-MS were systemically studied. Drug loaded HAP-MS was encapsulated by biodegradable PLGA using S/O/W emulsion–solvent evaporation method, and the in vitro drug release was tested. The adsorption kinetics of Dox·HCl onto HAP-MS fitted well to Freundlich model at lower drug concentrations, but when the HAP-MS was incubated in concentrated drug solutions higher than a critical concentration, precipitation of drug from solutions occurred. Rapid desorption or release of Dox·HCl from HAP-MS was observed. While, the release profile of Dox·HCl from PLGA coated microspheres showed steady slow drug release lasted for at least 7 days without obvious burst release. PLGA coated HAP-MS may provide a novel, injectable carrier for loading and long-period sustained release of small molecular, water-soluble drugs.     

Tracking the effect of microspheres size on the drug release from a microsphere/sucrose acetate isobutyrate (SAIB) hybrid depot in vitro and in vivo

The effects of particle size of microspheres on the drug release from a microsphere/sucrose acetate isobutyrate (SAIB) hybrid depot (m-SAIB) was investigated to develop a long-term sustained release drug delivery system with low burst release both in vitro and in vivo. A model drug, risperidone, was first encapsulated into PLGA microspheres with different particle sizes using conventional emulsification and membrane emulsification methods. The m-SAIB was prepared by dispersing the risperidone-microspheres in the SAIB depot. The drug release from m-SAIB was double controlled by the drug diffusion from the microspheres into SAIB matrix and the drug diffusion from the SAIB matrix into the medium. Large microspheres (18.95?±?18.88?µm) prepared by the conventional homogenization method exhibited porous interior structure, which contributed to the increased drug diffusion rate from microspheres into SAIB matrix. Consequently, m-SAIB containing such microspheres showed rapid initial drug release (C_max?=_?110.1?±54.2?ng/ml) and subsequent slow drug release (C_s(4–54d)=?2.7?±?0.8?ng/ml) in vivo. Small microspheres (5.91?±?2.24?µm) showed dense interior structure with a decreased drug diffusion rate from microspheres into SAIB matrix. The initial drug release from the corresponding m-SAIB was significantly decreased (C_max?=_?40.9?±?13.7?ng/ml), whereas the drug release rate from 4 to 54 d was increased (C_s(4–54d)=4.1?±?1.0?ng/ml). By further decreasing the size of microspheres to 3.38?±?0.70?µm, the drug diffusion surface area was increased, which subsequently increased the drug release from the m-SAIB. These results demonstrate that drug release from the m-SAIB can be tailored by varying the size of microspheres to reduce the in vivo burst release of SAIB system alone.     

Controlled release of BSA by microsphere-incorporated PLGA scaffolds under cyclic loading

Localized delivery of bioactive molecules from porous biodegradable scaffolds is very important in advanced tissue engineering strategies, and it is necessary to study the delivery under dynamic loading which mimics the in vivo biomechanical environments. In this study, bovine serum albumin (BSA), a model of bioactive proteins, was incorporated into porous poly(l-lactide-co-glycolide) (PLGA) scaffolds by seeding BSA-loaded microspheres onto the scaffold pore wall, where the microspheres of poly(ethylene glycol)-b-poly(l-lactide) (PELA) were prepared by double emulsion technique. The in vitro release behavior of BSA from the scaffold under dynamic cyclic loading was studied in comparison with that under a static condition as well as from PELA microspheres. It was observed that the microsphere-incorporated scaffold prolonged BSA release with respect to the microspheres. The cyclic loading accelerated the release of BSA from the scaffold and the cumulative release on day 10 reached 85% of the totally encapsulated BSA. The delivery under a dynamic condition would be an initial study of in vivo localized delivery of growth factors.     

5-Fluorouracil encapsulated HA/PLGA composite microspheres for cancer therapy

5-Fluorouracil (5FU) was successfully entrapped within poly(lactide-co-glycolide) (PLGA) and hydroyapatite (HA) composite microspheres using the emulsification/solvent extraction technique. The effects of HA to PLGA ratio, solvent ratio as well as polymer inherent viscosity (IV) on encapsulation efficiency were investigated. The degradation and drug release rates of the microspheres were studied for 5?weeks in vitro in phosphate buffered solution of pH 7.4 at 37?°C. The drug release profile followed a biphasic pattern with a small initial burst followed by a zero-order release for up to 35?days. The initial burst release decreased with increasing HA content. The potential of HA in limiting the initial burst release makes the incorporation of HA into PLGA microspheres advantageous since it reduces the risk of drug overdose from high initial bursts. The linear sustained drug release profile over the course of 5?weeks makes these 5-FU-loaded HA/PLGA composite microparticles a promising delivery system for the controlled release of chemotherapy drugs in the treatment of cancer.     

In situ forming implants for the delivery of metronidazole to periodontal pockets: formulation and drug release studies

This study was performed to obtain prolonged drug release with biodegradable in situ forming implants for the local delivery of metronidazole to periodontal pockets. The effect of polymer type (capped and uncapped PLGA), solvent type (water-miscible and water-immiscible) and the polymer/drug ratio on in vitro drug release studies were investigated. In situ implants with sustained metronidazole release and low initial burst consisted of capped PLGA and N-methyl-2-pyrolidone as solvent. Mucoadhesive polymers were incorporated into the in situ implants in order to modify the properties of the delivery systems towards longer residence times in vivo. Addition of the polymers changed the adhesiveness and increased the viscosity and drug release of the formulations. However, sustained drug release over 10 days was achievable. Biodegradable in situ forming implants are therefore an attractive delivery system to achieve prolonged release of metronidazole at periodontal therapy.     

Manufacture,Characterization, and Release Profiles of Insulin-Loaded Mesoporous PLGA Microspheres

This paper reports the fabrication of insulin-loaded mesoporous microspheres by a double emulsion-solvent evaporation technique using poly(lactic acid-co-glycolic acid) (PLGA) as carrier materials. PLGA solutions with two different concentrations (4% and 5%) were used as the oil phases to fabricate the mesoporous microspheres. The morphology and the particle size distribution of final microspheres were studied by optical microscope, scanning electronic microscope (SEM), and Malvern 2600 sizer, respectively. The mesoporous microspheres were monodisperse with an average diameter of 7 ± 3.5 µm. Insulin, as a model drug, was encapsulated into the final microspheres. In vitro release studies suggested that insulin was continuously released from the medicated microspheres. Furthermore, the final microspheres obtained from 4% PLGA solution showed a small “burst release” effect for their dense structures, which shortened the lag time to the effective plasma concentration. To summarize, the insulin-loaded PLGA microsphere are very promising for use in pharmaceutical applications.     

Control of drug loading efficiency and drug release behavior in preparation of hydrophilic-drug-containing monodisperse PLGA microspheres

We prepared monodisperse poly(lactide-co-glycolide) (PLGA) microspheres containing blue dextran (BLD)—a hydrophilic drug—by membrane emulsification technique. The effects of electrolyte addition to the w₂ phase and significance of the droplet size ratio between primary (w₁/o) and secondary (w₁/o/w₂) emulsions during the preparation of these microspheres was examined. The droplet size ratio was evaluated from the effect of stirring rate of the homogenizer when preparing the primary emulsion. The drug loading efficiency of BLD in these microspheres increased with stirring rate. It increased to approximately 90% when 2.0% NaCl was added to the w₂ phase. Drug release from these microspheres was slower than that when they were prepared without electrolyte addition. Despite the very high efficiency drug release was gradual because BLD was distributed at the microspheres core. Relatively monodisperse hydrophilic-drug-containing PLGA microspheres with controlled drug loading efficiency and drug release behavior were prepared.     

Poly(lactide-co-glycolide) nanoparticles as carriers for norcantharidin

Norcantharidin (NCTD) is one of the new chemotherapy agents that have anti-tumor activity. However, the clinical potential of NCTD is limited by its high systemic toxicity, poor solubility in physiological environment and short half-life. In this paper, NCTD loaded poly(lactide-co-glycolide) (PLGA) nanoparticles for controlled delivery were prepared by using an interfacial deposition method. The resulting particles were characterized for their size, morphology, drug loading capacity, entrapment efficiency and in vitro drug release over an extended period of 12 days. The interfacial deposition technique succeeded in building a spherical, monodisperse nanoparticulate delivery system with high entrapment efficiency. The in vitro release lasts for more than 10 days showed a biphasic profile with an initial burst. The in vitro anti-tumor activity of NCTD-PLGA nanocapsules was assessed using the Human Hepatocellular Carcinoma cells SMMC-7721 by the MTT test. Ascites hepatoma (H-22H) and pulmonary adenocarcinoma (LA795) mice models were used to study the in vivo tumoricidal efficacy of NCTD delivery from the PLGA nanoparticles. The results demonstrate that i.v. or i.p. administration of this controlled release system could be of high clinical significance in cancer chemotherapy.     

Preparation and evaluation of a novel bioactive glass/lysozyme/PLGA composite microsphere

Objective: The objective of this study was to fabricate a novel nano-bioceramics incorporated lysozyme poly (d, l-lactide-co-glycolide) (PLGA) microsphere.

Methods: The nano-bioceramics was used as a biodegradable and sustained-release antacid to stabilize the lysozyme in the drug release process. First, the nano-bioceramics were prepared by sol-gel method, and then were characterized by energy dispersive X-ray analysis, dynamic light scattering and in vitro degradation test. Second, the lysozyme PLGA microsphere incorporated with nano-bioceramic was fabricated by the S/W/O/W emulsion solvent evaporation method. The microsphere was characterized by scanning electron microscopy (SEM), Fourier transform infrared (FTIR) spectroscopy and UV circular dichroism (UV CD). Finally the in vitro drug release and bioactivity test was carried out.

Results: The composition of the nano-bioceramics was 58% SiO₂, 36% CaO, 6% P₂O₅, and the average particle size was 295?nm. The nano-bioceramics incorporated lysozyme PLGA microspheres were prepared by the multi-emulsion method. The SEM results showed that the bioceramics was uniformly distributed in the PLGA microsphere. Results from in vitro lysozyme release test exhibited a prolonged release time for 1month. The FTIR and UVCD results suggested that the lysozyme in the drug release process had a similar secondary structure conformation to the native one. The Micrococcus lysodeikticus test showed that the microspheres incorporated with bioceramics provided long-term protein stability against the acidic environment resulted from PLGA’s degradates and more than 90% of the lysozyme released over the 1 month period was preserved in a bioactive form.

Conclusion: A novel bioceramics incorporated lysozyme PLGA microsphere was prepared with potentials for sustained protein release formulation.     

PLGA 50:50 nanoparticles of paclitaxel: Development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation

Clinical administration of paclitaxel is hindered due to its poor solubility, which necessitates the formulation of novel drug delivery systems to deliver such extreme hydrophobic drug. To formulate nanoparticles which makes suitable to deliver hydrophobic drugs effectively (intravenous) with desired pharmacokinetic profile for breast cancer treatment; in this context in vitro cytotoxic activity was evaluated using BT-549 cell line. PLGA nanoparticles were prepared by emulsion solvent evaporation technique and evaluated for physicochemical parameters, in vitro anti-tumor activity and in vivo pharmacokinetic studies in rats. Particle size obtained in optimized formulation was <200?nm. Encapsulation efficiency was higher at polymer-to-drug ratio of 20:1. In vitro drug release exhibited biphasic pattern with initial burst release followed by slow and continuous release (15?days). In vitro anti-tumor activity of optimized formulation inhibited cell growth for a period of 168?h against BT-549 cells. AUC_(0???) and t _1/2 were found to be higher for nanoparticles with low clearance rate.     

Double-walled microspheres loaded with meglumine antimoniate: preparation,characterization and in vitro release study

Objective: The objective of this study was to fabricate double-walled poly(lactide-co-glycolide) (PLGA) microspheres to increase encapsulation efficiency and avoid rapid release of hydrophilic drugs such as meglumine antimoniate.

Methods: In this study, double-walled and one-layered microspheres of PLGA were prepared using the emulsion solvent evaporation technique to better control the release of a hydrophilic drug, meglumine antimoniate (Glucantime®), which is the first choice treatment of cutaneous leishmaniasis. The effect of hydrophobic coating on microspheres' size, morphology, encapsulation efficiency and drug release characteristics was evaluated. Furthermore, the presence of antimony in meglumine antimoniate made it possible to observe the drug distribution within the microspheres' cross section by means of energy dispersive X-ray spectroscopy.

Results: Drug distribution images confirmed accumulation of the drug within the inner core of double-walled microspheres. In addition, these microspheres encapsulated the drug more efficiently up to 87% and demonstrated reduced initial burst and prolonged release compared to one-layered microspheres. These superiorities make double-walled microspheres an optimum candidate for sustained delivery of hydrophilic drugs.

Conclusion: Double-walled microspheres provide some advantages over traditional microspheres overcoming most of their limitations. Double-walled microspheres were found to be more efficient than their corresponding one-layered microspheres in terms of encapsulation efficiencies and release characteristics.     

Development and in vitro characterization of chitosan-coated polymeric nanoparticles for oral delivery and sustained release of the immunosuppressant drug mycophenolate mofetil

Objective: To develop an oral sustained release formulation of mycophenolate mofetil (MMF) for once-daily dosing, using chitosan-coated polylactic acid (PLA) or poly(lactic-co-glycolic) acid (PLGA) nanoparticles. The role of polymer molecular weight (MW) and drug to polymer ratio in encapsulation efficiency (EE) and release from the nanoparticles was explored in vitro.

Methods: Nanoparticles were prepared by a single emulsion solvent evaporation method where MMF was encapsulated with PLGA or PLA at various polymer MW and drug: polymer ratios. Subsequently, chitosan was added to create coated cationic particles, also at several chitosan MW grades and drug: polymer ratios. All the formulations were evaluated for mean diameter and polydispersity, EE as well as in vitro drug release. Differential scanning calorimetry (DSC), surface morphology, and in vitro mucin binding of the nanoparticles were performed for further characterization.

Results: Two lead formulations comprise MMF: high MW, PLA: medium MW chitosan 1:7:7 (w/w/w), and MMF: high MW, PLGA: high MW chitosan 1:7:7 (w/w/w), which had high EE (94.34% and 75.44%, respectively) and sustained drug release over 12?h with a minimal burst phase. DSC experiments revealed an amorphous form of MMF in the nanoparticle formulations. The surface morphology of the MMF NP showed spherical nanoparticles with minimal visible porosity. The potential for mucoadhesiveness was assessed by changes in zeta potential after incubation of the nanoparticles in mucin.

Conclusion: Two chitosan-coated nanoparticles formulations of MMF had high EE and a desirable sustained drug release profile in the effort to design a once-daily dosage form for MMF.     

Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis

Poly(lactic-co-glycolic acid) microspheres loaded with imatinib mesylate has been developed as a new therapeutic strategy to prevent craniopharyngioma recurrence. Microspheres composed of different lactic/glycolic acid ratios, molecular weights and drug compositions were synthesized and loaded with imatinib mesylate by modified double-emulsion/solvent evaporation technique and subsequently characterized by particle-size distribution, scanning electron microscopy, encapsulation efficiency and in vitro drug release. Inhibitory potential of imatinib containing microspheres on tumor neovascularization was investigated on craniopharyngioma tumor samples by rat cornea angiogenesis assay. Results showed that microspheres in different LA:GA ratios [LA:GA 50:50 (G50), 75:25 (G25), 85:15 (G15)] considerably reduced neovascularization induced by recurrent tumor samples in an in vivo angiogenesis assay (P < 0.01). Our data indicate that local delivery of imatinib mesylate to the post-surgical tumoral cavity using biodegradable microspheres may be a promising biologically selective approach to prevent the recurrence of craniopharyngiomas, via inhibition of neovascularization.     

Taste masking of azithromycin by resin complex and sustained release through interpenetrating polymer network with functionalized biopolymers

Abstract

Objective: The objective was to evaluate taste masking of azithromycin (AZI) by ion exchange resins (IERs) and the formation of covalent semi interpenetrating polymer network (IPN) beads using chitosan (CS) and sodium carboxylated agarose (SCAG) for sustained release of drug.

Methods: Methacrylic acid (MAA)-based IERs were prepared by suspension polymerization method. Drug release complexes (DRCs) were prepared by different drug:resin ratios i.e. 1:1, 1:2 and 1:4. The resultant DRCs were characterized using DSC, FTIR, PXRD, in vivo and in vitro taste masking, and in vitro drug release at gastric pH. IPN beads were prepared by entrapping DRCs with bio polymers and cross linked with trisodium citrate (NaCIT), and further cross-linked with glutaraldehyde (GA) for sustained release of AZI.

Results: In vitro and in vivo taste masking studies showed that MD1:4 DRC formulation was optimal. The release of AZI from DRC was found to be very fast at gastric pH i.e. 97.37?±?1.02% within 45?min. The formation of IPN beads was confirmed by FTIR. The release of drug from IPN beads at gastric and intestinal pH was found to be “<28% and <60%”, respectively. The release kinetics showed Fickian diffusion profile for ionically cross-linked beads and zero-order release mechanism for GA cross-linking beads.

Conclusions: DRCs can be effectively used for taste masking and newly formulated IPN beads demonstrated sustained release of AZI.     

Formulation and characterisation of poly(lactic‐co‐glycolic acid) encapsulated clove oil nanoparticles for dental applications

This study investigated synthesis and characterisation of Nano‐PLGA (poly(lactic‐co‐glycolic acid))/CO (clove‐oil) nanoparticles. The delivery of drug‐loaded nanoparticles to demineralised dentin substrates and their morphological association with a two‐step etch‐and‐rinse adhesive system was studied. The effect of Nano‐PLGA/CO pretreatment on micro‐tensile bond strength of resin‐dentin bonding was scrutinised. This study employed CO‐containing PLGA nanoparticles as a delivery vehicle for sustainable drug release inside dentinal‐tubules for potential dental applications. Emulsion evaporation resulted in uniformly distributed negatively‐charged Nano‐PLGA/Blank and Nano‐PLGA/CO nanoparticles. Scanning electron microscopy/ transmission electron microscopy revealed even spherical nanoparticles with smooth texture. High CO‐loading and encapsulation were achieved. Moreover, controlled CO‐release was evidenced after 15 days, in‐vitro and ex‐vivo. Nanoparticles exhibited low initial toxicity towards human mesenchymal stem cells with excellent antibacterial properties. Nanoparticles penetration inside dentinal‐tubules indicated a close correlation with resin‐tags. Nano‐PLGA/CO pretreatment indicated reduction in short‐term bond strength of resin‐dentin specimens. Nano‐PLGA/CO as model drug‐loaded nanoparticles showed excellent metric and antibacterial properties, low toxicity and sustained CO release. However, the loading of nanoparticles with CO up to ∼10 mg (Nano‐PLGA/CO:10) did not adversely affect short‐term bond strength values. This drug‐delivery strategy could be further expanded to deliver other pulp‐sedative agents and medications with other dental relevance.Inspec keywords: nanoparticles, dentistry, encapsulation, filled polymers, nanofabrication, nanocomposites, nanomedicine, biomedical materials, drug delivery systems, adhesives, tensile strength, biomechanics, resins, proteins, molecular biophysics, biochemistry, emulsions, evaporation, scanning electron microscopy, transmission electron microscopy, texture, cellular biophysics, antibacterial activity, bonds (chemical)Other keywords: poly(lactic‐co‐glycolic acid) encapsulated clove oil nanoparticles, dental applications, drug‐loaded nanoparticle delivery, demineralised dentin substrates, morphological association, two‐step etch‐and‐rinse adhesive system, simulated pulpal pressure, nanoPLGA‐CO pretreatment, microtensile bond strength, resin‐dentin bonded specimens, CO‐containing PLGA nanoparticles, delivery vehicle, sustainable drug release, dentinal‐tubules, potential dental applications, emulsion evaporation, uniformly‐distributed negatively‐charged nanoPLGA‐blank, scanning electron microscopy‐transmission electron microscopy, spherical nanoparticles, smooth texture, high CO‐loading, controlled CO‐release, human mesenchymal stem cells, antibacterial properties, antibiofilm properties, deep nanoparticle penetration, resin‐tags, short‐term bond strength, resin‐dentin specimens, metric properties, antibacterial properties, sustained CO release, pulp‐sedative agents, time 15 d     

In vitro evaluation of the effects of various additives and polymers on nerve growth factor microspheres

Objective: To evaluate the effects of various additives or polymers on the in vitro characteristics of nerve growth factor (NGF) microspheres.

Materials and methods: NGF microspheres were fabricated using polyethylene glycol (PEG), ovalbumin (OVA), bovine serum albumin (BSA) or glucose as protein protectors, and poly(lactide-co-glycolide) (PLGA) or poly(lactic acid) (PLA)/PLGA blends as encapsulation materials.

Results: Encapsulation efficiencies of the NGF microspheres with various additives or polymers were not more than 30%. A comparative study revealed that OVA was somewhat superior over others, and was thus chosen as the protective additive in subsequent experiments. Polymer analysis showed that NGF release from 1:1 PLA (η?=?0.8):PLGA (75/25, η?=?0.45) microspheres lasted for 90?d with a burst release rate of 12.7%. About 40% of the original bioactivity was retained on the 28th day, while 10% was left on the 90th day.

Discussion and conclusion: The combination of OVA as an additive and the PLA/PLGA blend as the coating matrix is suitable for encapsulation of NGF in microspheres for extended release.     

pH-Sensitive oral insulin delivery systems using Eudragit microspheres

In this paper, we present in vitro and in vivo release data on pH-sensitive microspheres of Eudragit L100, Eudragit RS100 and their blend systems prepared by double emulsion-solvent evaporation technique for oral delivery of insulin. Of the three systems developed, Eudragit L100 was chosen for preclinical studies. Insulin was encapsulated and in vitro experiments performed on insulin-loaded microspheres in pH 1.2 media did not release insulin during the first 2?h, but maximum insulin was released in pH 7.4 buffer media from 4 to 6?h. The microspheres were characterized by scanning electron microscopy to understand particle size, shape and surface morphology. The size of microspheres ranged between 1 and 40?µm. Circular dichroism spectra indicated the structural integrity of insulin during encapsulation as well as after its release in pH 7.4 buffer media. The in vivo release studies on diabetic-induced rat models exhibited maximum inhibition of up to 86%, suggesting absorption of insulin in the intestine.     

Gellan gum microspheres crosslinked with trivalent ion: effect of polymer and crosslinker concentrations on drug release and mucoadhesive properties

Gellan gum microspheres were obtained by ionotropic gelation technique, using the trivalent ion Al³⁺. The percentage of entrapment efficiency ranged from 48.76 to 87.52% and 2² randomized full factorial design demonstrated that both the increase of polymer concentration and the decrease of crosslinker concentration presented a positive effect in the amount of encapsulated drug. Microspheres size and circularity ranged from 700.17 to 938.32?μm and from 0.641 to 0.796?μm, respectively. The increase of polymer concentration (1–2%) and crosslinker concentration (3–5%) led to the enlargement of particle size and circularity. However, the association of increased crosslinker concentration and reduced polymer content made the particles more irregular. In vitro and ex vivo tests evidenced the high mucoadhesiveness of microspheres. The high liquid uptake ability of the microspheres was demonstrated and the pH variation did not affect this parameter. Drug release was pH dependent, with low release rates in acid pH (42.40% and 44.93%) and a burst effect in phosphate buffer pH (7.4). The Weibull model had the best correlation with the drug release data, demonstrating that the release process was driven by a complex mechanism involving the erosion and swelling of the matrix or by non-Fickian diffusion.     

Dual cross-linked chitosan microspheres formulated with spray-drying technique for the sustained release of levofloxacin

Objective: This study was aimed to develop sustained drug release from levofloxacin (LF)-loaded chitosan (CS) microspheres for treating ophthalmic infections.

Significance: Dual cross-linked CS microspheres developed by the spray-drying technique displays significantly higher level of sustained drug release compared with non-cross-linked CS microspheres.

Methods: LF-loaded CS microspheres were prepared using the spray-drying technique, and then solidified with tripolyphosphate and glutaraldehyde as dual cross-linking agents. The microspheres were characterized by surface morphology, size distribution, zeta potential, encapsulation efficiency, and drug release profiles in vitro. The drug quantification was verified and analyzed by high-performance liquid chromatography (HPLC). The structural interactions of the CS with LF were studied with Fourier transform infrared spectroscopy. The effect of various influencing excipients in the formulation of the dual cross-linked CS microspheres on drug encapsulation efficiency and the drug release profiles were extensively investigated.

Result: The microspheres demonstrated high encapsulation efficiency (72.4?～?98.55%) and were uniformly spherical with wrinkled surface. The mean particle size was between 1020.7?±?101.9 and 2381.2?±?101.6?nm. All microspheres were positively charged (zeta potential ranged from 31.1?±?1.32 to 42.81?±?1.55?mV). The in vitro release profiles showed a sustained release of the drug and it was remarkably influenced by the cross-linking process.

Conclusion: This novel spray-drying technique we have developed is suitable for manufacturing LF-loaded CS microspheres, and thus could serve as a potential platform for sustained drug release for effective therapeutic application in ocular infections.     

Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation

The purpose of this study was to develop sustained release formulation of anastrozole-loaded chitosan microspheres for treatment of breast cancer. Chitosan microspheres cross-linked with two different cross-linking agents viz, tripolyphosphate (TPP) and glutaraldehyde (GA) were prepared using single emulsion (w/o) method. A reverse phase HPLC method was developed and used for quantification of drug in microspheres and rat plasma. Influence of cross-linking agents on the properties of chitosan microspheres was extensively investigated. Formulations were characterized for encapsulation efficiency (EE), compatibility of drug with excipients, particle size, surface morphology, swelling capacity, erosion and drug release profile in phosphate buffer pH 7.4. EE varied from 30.4 ± 1.2 to 69.2 ± 3.2% and mean particle size distribution ranged from 72.5 ± 0.5 to 157.9 ± 1.5 μm. SEM analysis revealed smooth and spherical nature of microspheres. TPP microspheres exhibited higher swelling capacity, percentage erosion and drug release compared to GA microspheres. Release of anastrozole (ANS) was rapid up to 4 h followed by slow release status. FTIR analysis revealed no chemical interaction between drug and polymer. DSC analysis indicated ANS trapped in the microspheres existed in amorphous form in polymer matrix. The highest correlation coefficients (R ²) were obtained for Higuchi model, suggesting a diffusion controlled mechanism. There was significant difference in the pharmacokinetic parameters (AUC_0−∞, Kel and t_1/2) when ANS was formulated in the form of microspheres compared to pure drug. This may be attributed to slow release rate of ANS from chitosan microspheres and was detectable in rat plasma up to 48 h which correlates well with the in vitro release data.